Nektar Therapeutics (NKTR) — Financial statements
Income statement, balance sheet, and cash flow for Nektar Therapeutics — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 55↓43.9% | 98↑9.2% | 90↓2.1% | 92↓9.7% | 102 | |
| Cost of Revenue | 0.00↓100.0% | 31↓16.3% | 37↑69.4% | 22↓13.1% | 25 | |
| Gross Profit | 55↓18.5% | 68↑26.7% | 53↓24.1% | 70↓8.6% | 77 | |
| Operating Expenses | ||||||
| R&D Expenses | 117↓3.0% | 121↑5.9% | 114↓47.7% | 218↓45.5% | 400 | |
| General & Administrative Expenses | 69↓10.5% | 77↓0.9% | 77↓16.2% | 92↓24.8% | 123 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 69↓10.5% | 77↓0.9% | 77↓16.2% | 92↓24.8% | 123 | |
| Other Expenses | 0.00↑100.0% | -25↓3556.8% | -0.68 | 0.00 | 0.00 | |
| Operating Expenses | 186↑7.6% | 173↓9.4% | 191↓38.5% | 311↓40.6% | 523 | |
| Total Costs & Expenses | 186↓8.7% | 204↓10.5% | 228↓31.5% | 332↓39.4% | 548 | |
| Operating Results | ||||||
| Operating Income | -131↓24.3% | -105↑23.5% | -137↑42.8% | -240↑46.1% | -446 | |
| Depreciation & Amortization | 1↓76.6% | 4↓43.8% | 8↓35.9% | 12↓13.8% | 14 | |
| EBITDA | -130↓49.7% | -87↑64.3% | -243↑24.9% | -324↑29.9% | -462 | |
| EBIT | -131↓43.6% | -91↑63.7% | -251↑25.3% | -336↑29.4% | -476 | |
| Interest & Other Income | ||||||
| Net Interest Income | -16↓15.7% | -14↓115.2% | -6↑71.4% | -22↑50.4% | -45 | |
| Interest Income | 10↓28.0% | 15↓23.7% | 19↑180.2% | 7↑148.4% | 3 | |
| Interest Expense | 26↓6.9% | 28↑11.0% | 25↓12.4% | 29↓38.9% | 47 | |
| Non-Operating Income | 0.00↑100.0% | -14↓112.4% | 113↑18.4% | 96↑220.9% | 30 | |
| Other Income / Expenses | -33↓138.8% | -14↑89.9% | -139↓11.3% | -125↓61.6% | -77 | |
| Income Before Tax | -164↓37.8% | -119↑56.9% | -276↑24.3% | -365↑30.3% | -523 | |
| Income Tax Expense | -0.14↑42.3% | -0.24↓19.5% | -0.20↓106.2% | 3↑477.2% | 0.56 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -164↓37.9% | -119↑56.9% | -276↑25.0% | -368↑29.7% | -524 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -164↓37.9% | -119↑56.9% | -276↑25.0% | -368↑29.7% | -524 | |
| Bottom-Line Net Income | -164↓37.9% | -119↑56.9% | -276↑25.0% | -368↑29.7% | -524 | |
| EPS (Basic) | -9.73↓12.1% | -8.68↑60.2% | -21.79↑26.2% | -29.51↑31.2% | -42.90 | |
| EPS (Diluted) | -9.73↓12.1% | -8.68↑60.2% | -21.79↑26.2% | -29.51↑31.2% | -42.90 | |
| Weighted Average Shares | 17↑23.0% | 14↑8.2% | 13↑1.5% | 12↑2.1% | 12 | |
| Weighted Average Diluted Shares | 17↑23.0% | 14↑8.2% | 13↑1.5% | 12↑2.1% | 12 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.